CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia

Future Oncology
Paula CramerMichael Hallek

Abstract

Four Phase II trials (clinical trials numbers: NCT02345863, NCT02401503, NCT02445131 and NCT02689141) evaluate a different combination of targeted agents in an all-comer population of approximately 60 patients with chronic lymphocytic leukemia irrespective of prior treatment, physical fitness and genetic risk factors. Patients with a higher tumor load start with a debulking treatment with bendamustine. The subsequent induction and maintenance treatment with an anti-CD20 antibody (obinutuzumab or ofatumumab) and a targeted oral agent (ibrutinib, idelalisib or venetoclax) are continued until achievement of a complete response and minimal residual disease negativity. This strategy represents a new era of chronic lymphocytic leukemia therapy where chemotherapy is increasingly replaced by targeted agents and treatment duration is tailored to the patient's individual tumor load and response.

References

Sep 5, 2002·Nature Reviews. Cancer·Suzanne Cory, Jerry M Adams
Feb 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian W FlinnMartin S Tallman
Mar 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tadeusz RobakSergey I Moiseev
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Dec 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew W RobertsRod Humerickhouse
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sebastian BöttcherMichael Kneba
May 24, 2012·Leukemia & Lymphoma·Matthew S Davids, Jennifer R Brown
Jun 2, 2012·Blood·Michael Hallek
Aug 8, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Oct 8, 2013·Immunology Letters·Lydia Scarfò, Paolo Ghia
Jan 10, 2014·The New England Journal of Medicine·Valentin GoedeMichael Hallek
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
May 30, 2014·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators
Jun 14, 2014·Blood·Sebastian Böttcher
Oct 11, 2014·Blood·Peter DregerUNKNOWN European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
Aug 19, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laurie H SehnOliver W Press
Oct 16, 2015·Nature·Dan A LandauCatherine J Wu
Apr 5, 2016·Seminars in Oncology·Kami Maddocks, Jeffrey A Jones

❮ Previous
Next ❯

Citations

Aug 11, 2018·Human Vaccines & Immunotherapeutics·J M L CasanS Opat
Feb 23, 2019·Expert Opinion on Pharmacotherapy·Taha Al Juhaishi, Victor Yazbeck
Jun 13, 2019·Hematological Oncology·Michael Hallek, Moritz Fürstenau
Jan 17, 2020·HemaSphere·Moritz FürstenauMichael Hallek
Nov 16, 2019·Leukemia & Lymphoma·Seema A Bhat, Jennifer A Woyach
Sep 27, 2019·Frontiers in Oncology·Ilaria Del GiudiceRobin Foà
Nov 15, 2019·HemaSphere·Deyan Y YosifovDaniel Mertens
Mar 31, 2019·Targeted Oncology·Fabienne Lucas, Jennifer A Woyach
Nov 30, 2019·Blood·Clemens-Martin Wendtner
Nov 12, 2021·Blood·Michael Y Choi
Oct 10, 2021·American Journal of Hematology·Michael Hallek, Othman Al-Sawaf

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies
flow cytometry
biopsy
PCR
exome sequencing

Clinical Trials Mentioned

NCT02950051

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.